US Drug Recall Register
Class III · Low risk Terminated Initiated Mar 15, 2013 (13 years ago)

Junel

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

What was recalled

Junel(TM) Fe 1.5/30 (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), 28 day regimen, Rx only, Barr laboratories, Pomona, NY --- NDC 0555-9028-58

Recalling firm
Teva Pharmaceuticals USA, Inc.
NDC code
0555-9028-58
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-682-2013

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Estradiol recalls

See all
Class II · Moderate risk Ongoing

Alyacen 7/7/7

Reason Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.

Glenmark Pharmaceuticals Inc., USA NDC 68462-556-29 D-0588-2026
Class II · Moderate risk Ongoing

Estradiol Gel

Reason Defective Container; packets were found to be either empty or partially full.

ANI Pharmaceuticals, Inc. NDC 70954-531-20 D-0543-2026
Class II · Moderate risk Ongoing

Estradiol

Reason Presence of Foreign substance - potential presence of metal particulate matter

F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0315-2026
Class II · Moderate risk Ongoing

Estradiol

Reason Presence of Foreign substance - potential presence of metal particulate matter

F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0314-2026
Class II · Moderate risk Ongoing

Estradiol

Reason Presence of Foreign substance - potential presence of metal particulate matter

F.H. INVESTMENTS, Inc. (dba Asteria Health) D-0313-2026